{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:11Z","timestamp":1792088171377,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of sotagliflozin in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Medline, Embase, the Cochrane Library, and grey literature sources up to August 2021 for randomized controlled trials (RCTs) that compared sotagliflozin with placebo or other antidiabetic agents in patients with type 2 diabetes. Our primary outcome was change in HbA1c from baseline. We additionally assessed three secondary efficacy and 15 safety outcomes. We synthesized data using weighted mean differences (WMDs) and odds ratios (ORs), along with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 11 RCTs comprising 16\u2009411 subjects in the meta\u2010analysis. Compared with placebo, sotagliflozin reduced HbA1c (WMD \u22120.42%, 95% CI \u22120.56 to \u22120.29), body weight (WMD \u22121.33\u2009kg, 95% CI \u22121.57 to \u22121.09), and systolic blood pressure (WMD \u22122.44\u2009mmHg, 95% CI \u22122.81 to \u22122.07). No difference was evident against other active comparators. Sotagliflozin reduced myocardial infarction (OR 0.72, 95% CI 0.54 to 0.97) and heart failure (OR 0.68, 95% CI 0.58 to 0.79) compared with placebo, and had a neutral effect on all\u2010cause mortality, cardiovascular mortality, and stroke. Treatment with sotagliflozin was safe regarding the incidence of serious adverse events, hypoglycaemia, and diabetic ketoacidosis. Nevertheless, it was associated with an increased incidence of diarrhoea, genital infections, and volume depletion events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sotagliflozin reduces blood glucose, body weight, and systolic blood pressure, and demonstrates a beneficial effect on heart failure and myocardial infarction. Its overall safety profile is comparable with other sodium\u2010glucose co\u2010transporter\u20102 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14555","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T21:48:28Z","timestamp":1632174508000},"page":"106-114","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Sotagliflozin for patients with type\n                    <scp>2<\/scp>\n                    diabetes: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-1342","authenticated-orcid":false,"given":"Ioannis","family":"Avgerinos","sequence":"first","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Diabetes Centre, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-0574","authenticated-orcid":false,"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Diabetes Centre, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-9819","authenticated-orcid":false,"given":"Panagiota","family":"Kakotrichi","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-938X","authenticated-orcid":false,"given":"Theodoros","family":"Michailidis","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Diabetes Centre, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-2979","authenticated-orcid":false,"given":"Aris","family":"Liakos","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Diabetes Centre, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6504-0036","authenticated-orcid":false,"given":"David R.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism Churchill Hospital  Oxford UK"},{"name":"Harris Manchester College University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-4072","authenticated-orcid":false,"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Diabetes Centre, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Harris Manchester College University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-3835","authenticated-orcid":false,"given":"Eleni","family":"Bekiari","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence\u2010Based Medicine Unit, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"},{"name":"Diabetes Centre, Second Medical Department Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14451"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0864"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05039-w"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz258"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114563304"},{"key":"e_1_2_9_7_1","unstructured":"European Medicines Agency. First oral add\u2010on treatment to insulin for treatment of certain patients with type 1 diabetes.https:\/\/www.ema.europa.eu\/en\/news\/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes. Accessed March 14 2020."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.03.001"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1259"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00182"},{"key":"e_1_2_9_14_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2","author":"Deeks JJ","year":"2021"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1549459"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0890"},{"key":"e_1_2_9_17_1","unstructured":"A randomized double\u2010blind placebo\u2010controlled 3\u2010arm parallel\u2010group 52\u2010week multicenter study to evaluate the efficacy and safety of sotagliflozin in patients with type 2 diabetes mellitus and moderate renal impairment who have inadequate glycemic control. Clinicaltrialsregister.eu identifier: 2016\u2010004889\u201026.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004889-26\/results. Accessed January 23 2021."},{"key":"e_1_2_9_18_1","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment [published online ahead of print August 2, 2021]","author":"Cherney DZI","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_9_19_1","unstructured":"A 26\u2010week randomized double\u2010blind controlled parallel\u2010group multicenter study to evaluate the efficacy and safety of sotagliflozin compared to empagliflozin and placebo in patients with type 2 diabetes who have inadequate glycemic control on dipeptidyl peptidase 4 inhibitor (DPP4[i]) with or without metformin. Clinicaltrialsregister.eu identifier: 2016\u2010001803\u201022.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001803-22\/results. Accessed January 23 2021."},{"key":"e_1_2_9_20_1","unstructured":"A randomized double\u2010blind parallel\u2010group 2\u2010treatment multiple dose study to assess the intestinal metabolic and cardiovascular effects of an 8\u2009weeks treatment with sotagliflozin once daily (QD) as compared with empagliflozin QD in type 2 diabetes mellitus (T2DM) subjects with mild to moderate hypertension. Clinicaltrialsregister.eu identifier: 2017\u2010002309\u201036.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002309-36\/results. Accessed January 23 2021."},{"key":"e_1_2_9_21_1","unstructured":"A 52\u2010week randomized double\u2010blind double\u2010dummy active and placebo\u2010controlled parallel\u2010group multicenter study to evaluate the efficacy and safety of sotagliflozin compared to glimepiride or placebo added to metformin in patients with type 2 diabetes who have inadequate glycemic control with metformin monotherapy. Clinicaltrialsregister.eu identifier: 2016\u2010001801\u201017.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001801-17\/results. Accessed January 23 2021."},{"key":"e_1_2_9_22_1","unstructured":"A randomized double\u2010blind placebo\u2010controlled parallel\u2010group 52\u2010week multicenter study to evaluate the efficacy and safety of sotagliflozin in patients with type 2 diabetes who have inadequate glycemic control on basal insulin alone or in addition to oral antidiabetes drugs (OADs). Clinicaltrialsregister.eu identifier: 2016\u2010001804\u201043.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001804-43\/results. Accessed January 23 2021."},{"key":"e_1_2_9_23_1","unstructured":"A randomized double\u2010blind placebo\u2010controlled parallel\u2010group multicenter study to evaluate the efficacy and safety of sotagliflozin added to metformin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin. Clinicaltrialsregister.eu identifier: 2016\u2010001800\u201049.https:\/\/www.clinicaltrialsregister.eu\/ctr\u2010search\/trial\/2016\u2010001800\u201049\/results. Accessed January 23 2021."},{"key":"e_1_2_9_24_1","unstructured":"A randomized double\u2010blind placebo\u2010controlled parallel\u2010group multicenter study to evaluate the efficacy and safety of sotagliflozin added to a sulfonylurea alone or in combination with metformin in patients with type 2 diabetes who have inadequate glycemic control on a sulfonylurea alone or with metformin. Clinicaltrialsregister.eu identifier: 2016\u2010002826\u201035.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002826-35\/results. Accessed January 23 2021."},{"key":"e_1_2_9_25_1","unstructured":"BhattDL SzarekM StegPG et al.Benefits of SGLT1\/2 inhibition with sotagliflozin in heart failure with preserved ejection fraction. Conference Proceedings of the Annual Meeting of the American College of Cardiology (virtual) 2021.https:\/\/www.acc.org\/education-and-meetings\/image-and-slide-gallery\/~\/media\/B0EE906FD2D34B6AA29900BCE0681B8E.pdf. Accessed June 11 2021."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14374"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.12.007"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2008.036"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14555","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:19:48Z","timestamp":1761891588000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/dom.14555"],"URL":"https:\/\/doi.org\/10.1111\/dom.14555","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14555\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v2\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/review7","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14555\/v1\/review4","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"assertion":[{"value":"2021-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}